Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

A sputum sample analysis at the Blue House Clinic in Kenya, 2011. Photograph by Bruno De Cock
Press release
Press release |
25 September 2018
Tuberculosis

Global leaders must make bold commitments at first-ever UN tuberculosis summit

5 min
Kibera is one of the largest slums in Kenya. Here, MSF offers care to a neglected population isolated from basic healthcare standards due to hardships of poverty, Kenya 2011. Photograph by Bruno De Cock
Press release
Press release |
18 September 2018
Tuberculosis

MSF response to release of WHO’s Global Tuberculosis Report 2018

3 min
In March 2017, organisations from 17 European countries filed an opposition to Gilead Science's patent on the highly effective hepatitis C drug sofosbuvir. On 13th and 14th of September 2018, the hearing took e place before the European Patent Office in Munich. Photograph by Peter Bauza
Press release
Press release |
13 September 2018
Hepatitis C
Europe

MSF response to ruling in Gilead sofosbuvir patent hearing at European Patent Office

2 min
First set of free Hepatitis C medicines Sofosbuvir and Daclatasvir provided by Delhi Govt. run GB Pant hospital. Photograph by Garvit Nangia Photograph by Garvit Nangia
Press release
Press release |
11 September 2018
Hepatitis C
Europe

Civil society groups call for end to Gilead’s unwarranted hepatitis C drug monopoly in Europe

5 min
Emmanuel arrived at the Nsanje district hospital with advanced HIV and related opportunistic infections cryptococcal meningitis and TB. He underwent a lumbar puncture to evacuate fluid creating pressure in the spinal column and brain caused by cryptococcal meningitis, Malawi 2017. Photograph by Luca Sola
Press release
Press release |
30 August 2018
Tropical & neglected diseases
United States of America

FDA adds new diseases to list of those eligible for flawed government incentive

4 min
XDR-TB patient Hanif, taking his daily TB medication at home in the Govandi area of Mumbai, 2016. Photograph by Atul Loke
Press release
Press release |
17 August 2018
Tuberculosis

MSF applauds the World Health Organization’s move to recommend improved tuberculosis treatment options

5 min
First set of free Hepatitis C medicines Sofosbuvir and Daclatasvir provided by Delhi Govt. run GB Pant hospital. Photograph by Garvit Nangia Photograph by Garvit Nangia
Press release
Press release |
16 August 2018
Hepatitis C
China

Gilead loses monopoly control of its blockbuster hepatitis C medicine in China

3 min
MSF TB-MDR patients and Green House photos in Mathare. Photograph by Matthias Steinbach
Press release
Press release |
27 July 2018
Tuberculosis

Update on contentious negotiations for the UN High-level Meeting on Tuberculosis

3 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury